Suppr超能文献

血浆代用品

Plasma substitutes.

作者信息

Boldt J, Suttner S

机构信息

Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt, Ludwigshafen, Germany.

出版信息

Minerva Anestesiol. 2005 Dec;71(12):741-58.

Abstract

Adequate restoration of intravascular volume remains an important therapeutic manoeuvre in managing the surgical, medical and the critically ill intensive care patient. Definition of the ideal volume replacement strategy still remains one of the burning problems. The choice between colloid and crystalloid solutions continues to generate controversy. The highly controversial crystalloid/colloid dispute has been enlarged to a colloid/colloid debate because aside of the natural colloid albumin several non-protein (synthetic) colloids are available as plasma substitutes (e.g. dextrans, gelatins, hydroxyethyl starch [HES] solutions). Due to their varying physico-chemical properties, these solutions widely differ with regard to their pharmacokinetic and pharmacodynamic properties as well as to their hemodynamic efficacy and side-effects. HES is the most intensively studied plasma substitute. The different HES preparations are defined by concentration, molar substitution (MS), mean molecular weight (MW), and the C2/C6 ratio of substitution. Two new HES specification, a third-generation HES with a lower Mw and a lower MS (6% HES 130/0.4) than all other HES preparation and a first-generation HES prepared in a balanced solution, may be promising by improving the therapy of the hypovolemic patient. Albumin cannot be recommended for correction of hypovolemia because of ist extreme costs and because it can easily be replaced by other no-protein colloids. Dextrans should also not be used any more due to the negative effects on coagulation and its high anaphylactic potency. The historical crystalloid/colloid controversy has been focused primarily on outcome. There is increasing evidence that outcome (mortality) is not the correct measure when assessing the ideal volume replacement strategy. New concepts about critical care such as organ perfusion and organ function, the role of inflammation, immunological aspects, and wound healing may change this point of view. Volume replacement has been hitherto often based on art, dogma and personal beliefs. Further well-performed studies in this area will help more to shed new light on the ideal volume replacement strategy of the hypovolemic patient than more meta-analyses that are pooling old-to-very old studies to solve this problem.

摘要

在外科手术、内科及危重症监护患者的治疗中,充分恢复血管内容量仍是一项重要的治疗手段。理想的容量替代策略的定义仍然是亟待解决的问题之一。胶体溶液和晶体溶液之间的选择一直存在争议。极具争议的晶体/胶体之争已扩大为胶体/胶体之争,因为除天然胶体白蛋白外,还有几种非蛋白(合成)胶体可作为血浆替代品(如右旋糖酐、明胶、羟乙基淀粉[HES]溶液)。由于它们的物理化学性质各不相同,这些溶液在药代动力学和药效学性质、血流动力学效应及副作用方面差异很大。HES是研究最深入的血浆替代品。不同的HES制剂由浓度、摩尔取代度(MS)、平均分子量(MW)以及取代度的C2/C6比值来定义。两种新的HES规格,一种是分子量和MS比其他所有HES制剂都低的第三代HES(6% HES 130/0.4),另一种是在平衡溶液中制备的第一代HES,可能会通过改善低血容量患者的治疗效果而大有前景。由于白蛋白成本极高且很容易被其他非蛋白胶体替代,因此不建议用于纠正低血容量。由于对凝血有负面影响且过敏反应发生率高,也不应再使用右旋糖酐。历史上的晶体/胶体之争主要集中在治疗结果上。越来越多的证据表明,在评估理想的容量替代策略时,治疗结果(死亡率)并非正确的衡量标准。诸如器官灌注和器官功能、炎症的作用、免疫学方面以及伤口愈合等危重症护理的新概念可能会改变这一观点。迄今为止,容量替代往往基于经验、教条和个人信念。与更多将旧研究甚至非常古老的研究汇总以解决这一问题的荟萃分析相比,该领域进一步开展的高质量研究将更有助于阐明低血容量患者理想的容量替代策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验